|
| Press Releases |
|
 |
|
| Wednesday, March 23, 2022 |
|
|
Alset International Ltd establishes Alset Mining Pte Ltd to embark on cryptocurrency mining activities |
| Singapore Exchange-listed Alset International Ltd (SGX Stock Code: 40V) ("Alset", the "Company" or together with its subsidiaries, the "Group) wishes to announce that the Company has plans to embark on cryptocurrency mining business through its subsidiary Alset Mining Pte. Ltd. ("Alset Mining"). more info >> |
|
| Monday, February 21, 2022 |
|
|
Alset Capital Acquisition Corp. Announces Closing of Initial Public Offering and Exercise of Full Over-Allotment Option |
| Alset Capital Acquisition Corp. (the "Company") announced on February 3, 2022 the closing of its initial public offering of 7,500,000 units at $10.00 per unit (the "Offering"). more info >> |
|
| Monday, October 5, 2020 |
|
|
Impact BioMedical to Begin Efficacy Testing Pan-Coronavirus Vaccine Under New Wholly Owned Subsidiary Innate Immune, Inc. |
| Document Security Systems, Inc. today announced its wholly owned subsidiary Impact BioMedical, Inc. ("Impact BioMedical") has formed a new wholly owned subsidiary, Innate Immune, Inc. ("Innate Immune"), to initiate efficacy testing of a pancoronavirus vaccine, a special type of vaccine designed to protect against multiple coronaviruses. more info >> |
|
| Friday, September 18, 2020 |
|
|
Impact BioMedical Demonstrates 10-Fold Reduction in Viral Population of COVID-19 in Surface Disinfectant Efficacy Testing of its 3F Antiviral Biofragrance |
| Document Security Systems, Inc. (NYSE American: DSS) today announced its wholly owned subsidiary Impact BioMedical, Inc., through its subsidiary Global BioLife, Inc., completed efficacy testing of its proprietary 3F Antiviral Biofragrance at a biosafety level 3 containment facility at an independent university. more info >> |
|
| Friday, July 31, 2020 |
|
|
Impact Biomedical initiates Quantum, a new frontier in Pharmaceutical Development |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat. more info >> |
|
| Wednesday, June 24, 2020 |
|
|
Impact Biomedical Achieves COVID-19 Success with Equivir and 3F Biofragrance |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that they proved in vitro success of Equivir and 3F Biofragrance against COVID-19 in independent laboratory testing. more info >> |
|
| Wednesday, June 17, 2020 |
|
|
Impact Biomedical Announces Publication of COVID-19 Research in Peer-Reviewed Journal |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc. ("Impact Biomedical") announced today that their COVID-19 research with Global Research and Discovery Group Sciences ("GRDG"), conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. ("Vilotos"), was published in the peer-reviewed scientific journal Molecules on June 11, 2020. more info >> |
|
| Monday, June 1, 2020 |
|
|
Impact Biomedical and GRDG Sciences Announce Medical Technology Package Valued at USD 1.39 Billion (SGD 1.97 Billion) by Independent Experts |
| SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly owned subsidiary, Impact Biomedical Inc., would like to update its stakeholders on its suite of antiviral and medical technologies. more info >> |
|
| Friday, April 24, 2020 |
|
|
Impact Biomedical's Majority Owned Next Generation Medical Technologies Valued at USD 592 Million (SGD 841 Million) by Independent Experts |
| SGX-listed Singapore eDevelopment Ltd's (SeD; SGX:40V) wholly owned subsidiary Impact Biomedical Inc., announced recently that their suite of antiviral and medical technologies, co-owned with its partners, is valued at USD 592 Million (SGD 841 Million). Impact Biomedical's effective ownership of 64.53% in the suite of technologies equates to a value of USD 382 Million (SGD 542 Million). more info >> |
|
| Wednesday, March 18, 2020 |
|
|
Impact BioMedical's Linebacker and Equivir inhibit SARS-CoV-2, virus responsible for the COVID-19 outbreak |
| Singapore Exchange-listed Singapore eDevelopment Limited has announced that its wholly-owned U.S. biomedical subsidiary, Impact BioMedical, Inc., has, through its scientific research partner, GRDG Sciences, LLC. ("GRDG"), recently conducted molecular docking studies, utilizing advanced computational models, which indicate Linebacker and Equivir successfully inhibit infection of SARS-CoV-2, the virus responsible for the COVID-19 outbreak. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
TACACS.net: Strengthening Network Security with Native Active Directory Integration
Dec 5, 2024 06:30 HKT/SGT
|
|
|
Maxon One Winter Release Brings Holiday Cheer from Concept to Render
Dec 5, 2024 00:00 HKT/SGT
|
|
|
中信国际电讯CPC荣获三项业界大奖 内外展现网络安全实力
Dec 4, 2024 23:05 HKT/SGT
|
|
|
中信國際電訊CPC榮獲三項業界大獎 內外展現網絡安全實力
Dec 4, 2024 23:00 HKT/SGT
|
|
|
Naoris Protocol announces World's First Post-Quantum DePIN for Cybersecurity & Digital Trust ahead of Testnet
Dec 4, 2024 22:26: JST
|
|
|
Autobrains and JOYNEXT Revolutionize Smart Camera Solution Powered by Autobrains' Affordable Safety ADAS Software
Dec 4, 2024 22:20 HKT/SGT
|
|
|
CITIC Telecom CPC's Internal and External Cybersecurity Excellence Honored with 3 Industry Awards
Dec 4, 2024 22:10 HKT/SGT
|
|
|
25th Hong Kong Forum concludes successfully
Dec 4, 2024 22:00: JST
|
|
|
Naoris Protocol announces World's First Post-Quantum DePIN for Cybersecurity & Digital Trust ahead of Testnet
Dec 4, 2024 21:26 HKT/SGT
|
|
|
25th Hong Kong Forum concludes successfully
Dec 4, 2024 21:00 HKT/SGT
|
|
|
DENSO Signs Memorandum of Understanding with Canatu of Finland for Practical Application of Carbon Nanotube Technology
Dec 4, 2024 17:51 JST
|
|
|
Sweetness Affecting Both the Young and Old: Prevent Diabetes with LAC This World Diabetes Day
Dec 4, 2024 14:30 HKT/SGT
|
|
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Dec 4, 2024 11:08 HKT/SGT
|
|
|
雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果
Dec 4, 2024 10:59 HKT/SGT
|
|
|
云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验阶段性数据中取得积极结果
Dec 4, 2024 10:48 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
